Close Menu

NEW YORK – ArcherDx announced this week that its next generation sequencing device to detect neurotrophic receptor tyrosine kinase (NTRK) gene fusions that lead to cancer received breakthrough device designation from the US Food and Drug Administration. The device is under development as a companion diagnostic and uses Anchored Multiplex PCR chemistry to capture DNA, RNA, or ctDNA from blood and tissue samples.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.